Considering the high clinical impact and the dismal prognosis of ERCC6L2-mutated AML in the published cohorts, ERCC6L2 should be included in the initial assessment for both BFM and MDS/AML. This evidence concerns the gene ERCC6L2 and acute myeloid leukemia.